| Renal impairment did not appear to impact the pharmacokinetic properties of oral semaglutide following ten consecutive once-daily doses. |
| Oral semaglutide was well-tolerated in subjects with varying degrees of renal impairment. |
| These data suggest that renal impairment should not affect the dosing recommendations of oral semaglutide. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.